Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAM-FR
- Development stage
- Preclinical
- Lead developer
- Precirix
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CAM-FR is a targeted radiopharmaceutical being developed by Precirix for the treatment of folate receptor alpha (FRα)-expressing tumors, specifically ovarian cancer. It consists of a camelid-derived single-domain antibody (sdAb) that binds with high affinity and specificity to FRα, a protein overexpressed in approximately 75-90% of epithelial ovarian cancers. The sdAb format, also known as a nanobody, offers significant advantages over traditional monoclonal antibodies, including a smaller molecular size that enables rapid tumor penetration and fast blood clearance. These properties help minimize off-target radiation exposure and reduce kidney retention, which is a common challenge for folate-targeted therapies. By delivering a therapeutic radionuclide directly to the tumor site, CAM-FR aims to provide a potent and precise treatment for advanced ovarian cancer. The program is currently in the IND-enabling stage of development.
- Other names
- Precirix FRα-sdAb radiopharmaceuticalFolate Receptor alpha-single-domain antibody-radiopharmaceutical
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on CAM-FR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAM-FR.